MARKET WIREYahoo • 13h ago
Do Options Traders Know Something About Qiagen Stock We Don't?Investors need to pay close attention to QGEN stock based on the movements in the options market lately.
Why QGEN Stock Traded Steady Today — RQD Quant Desk Flash
$50.34 +0.02% NYSE • Public Delayed / 60s Snapshot
Qiagen N.V. (QGEN) receives a Roarable Rating of D (Sell) and flashes a Red SELL / AVOID warning (65/100 RQD Confidence). Our SEC filing scanner spotted paper earnings outpacing real operating cash flow (+222.9% (NI vs OCF)) while unpaid customer invoices grew—a classic sign to step aside until cash flow catches up.
ROARABLE D • SELL / AVOID
Cap $10.37B
INTERACTIVE SCENARIO DECK:
RQD QUANT TACHOMETERSELL / AVOID • D
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
5-PILLAR SNOWFLAKE RADARRw D+ · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE+3.2% Base Target
WHALE OPTIONS TUG-OF-WAR:54% Call Buyers ($2.4M)
46% PutsMax Pain: $49.00
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why QGEN Stock Traded Steady Today — RQD Quant Desk Flash
Qiagen N.V. (QGEN) advanced +0.02% to $50.34 as options desks priced 54% call premium vs. 46% put protection around the $49 max-pain magnet. Accounting Warning: Paper earnings outpaced operating cash flow (+222.9% (NI vs OCF)) as receivables rose.
- ▸Technical Tape: Trading at 70% of its 52-week range ($32.53 – $57.82) with RSI-14 at 71.9 (OVERBOUGHT (>70)).
- ▸Whale Options Positioning: $2.4M in bullish call flow vs. $2.1M in put flow (Put/Call 0.84x, implied earnings swing ±6.7%).
- ▸Primary SEC / Cross-Feed Trigger: QGEN Accounting Gap: Net Income (+220%) Outpaced OCF (-2.9%) With +-16.5% Working-Capital Build
Live QGEN Headlines & Catalysts
CATALYSTYahoo • 22h ago
Qiagen (QGEN) On Its €9.7b Takeover Deal Still Looks Fully ValuedQiagen (QGEN) is back in focus after agreeing to a €9.7b cash takeover by a consortium led by EQT XI at €46.50 per share, along with suspended 2026 guidance and a possible interim dividend. Qiagen’s share price has climb
MARKET WIREYahoo • 1d ago
Global Human Papillomavirus (HPV) Genotyping Panels Market Report 2026 | Capitalize on NGS, AI and Self-Collection Through 2030 with Roche, Abbott, Thermo Fisher and QIAGENDublin, Oct. 30, 2026 (GLOBE NEWSWIRE) -- "Human Papillomavirus (HPV) Genotyping Panels Market Global Report 2026" has been added to ResearchAndMarkets.com's offering. The global human papillomavirus (HPV) genotyping pan
CATALYSTYahoo • 1d ago
Clinical Genomics Interpretation Platforms Global Market Report 2026 | Capitalize on AI and Cloud Growth Through 2030 with Thermo Fisher, Illumina, QIAGEN, and Tempus AIDublin, Oct. 30, 2026 (GLOBE NEWSWIRE) -- "Clinical Genomics Interpretation Platforms Market Global Report 2026" has been added to ResearchAndMarkets.com's offering. The global clinical genomics interpretation platforms
RISK WATCHYahoo • 1d ago
Global CRISPR Fluorescence Assays Market Report 2026 | Capitalize on 19.5% CAGR to 2030 with Thermo Fisher, Merck, QIAGEN, and Mammoth Biosciences Driving Multiplex DiagnosticsBoost ROI via multiplex, AI-enabled and point-of-care assays; expand personalized diagnostics and localize reagent production to reduce tariff exposure.Dublin, Oct. 30, 2026 (GLOBE NEWSWIRE) -- "Clustered Regularly Inter
RISK WATCHYahoo • 1d ago
Global De Novo Genome Assembly Market 2026: Size, Share, Trends, and Forecast to 2030 | Capitalize on AI and Cloud Genomics with Illumina, PacBio, Oxford Nanopore, and QIAGENBoost ROI with AI-driven, cloud-based automation, high-throughput sequencing, custom analytics, and localized tools and reagents to reduce tariff costs.Dublin, Oct. 30, 2026 (GLOBE NEWSWIRE) -- "De Novo Genome Assembly G
MARKET WIREYahoo • 1d ago
Global Gene Panel Reconciliation Services Market Report 2026 | Capitalize on AI-Driven Genomics as Roche, Thermo Fisher, Illumina and QIAGEN Accelerate a $2.38B Market by 2030Players: Roche, Thermo Fisher, IQVIA, Labcorp, Eurofins. Profiled: gene-panel design, harmonization, interpretation, reporting, technologies, applications and regions.Dublin, Oct. 30, 2026 (GLOBE NEWSWIRE) -- "Gene Panel
CATALYSTYahoo • 2d ago
Global Reverse Transcription Kits Market Report 2026 | Capitalize on 8.4% CAGR as Roche, Thermo Fisher, Merck, QIAGEN and Promega Accelerate Automation and NGSDublin, Oct. 29, 2026 (GLOBE NEWSWIRE) -- "Reverse Transcription Kits Global Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global reverse transcription kits market is experiencing strong gr
MARKET WIREYahoo • 2d ago
Single-Cell eQTL Clinical Workflows Market Forecast to Reach $4.51 Billion by 2030 | Capitalize on 19.9% CAGR with Illumina, QIAGEN, 10x Genomics, Singleron and MoreDublin, Oct. 29, 2026 (GLOBE NEWSWIRE) -- "Single-Cell Expression Quantitative Trait Locus (EQTL) Clinical Workflows Global Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global single-cell
MARKET WIREYahoo • 2d ago
Urine Tumor Deoxyribonucleic Acid (DNA) Testing Global Market Report 2026 | Capitalize on 14.9% CAGR as Roche, Illumina, QIAGEN and Pangea Scale AI-Driven Liquid BiopsiesCompany profiles cover urine tumor DNA testing products, technologies, applications and market activity.Dublin, Oct. 29, 2026 (GLOBE NEWSWIRE) -- "Urine Tumor Deoxyribonucleic Acid (DNA) Testing Global Market Report 2026
🔴 SUNDAY NIGHT PREP • 7:00 PM ETHosted Live by Perry Belcher & Guest Forensic Quant Desk
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring QGEN)
- ✓Live walkthrough of QGEN's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
RQD INSIDER CLUB UPGRADE$49/YEAR
Want Plain-English AI Custom Indicators, Daily Pro Trader Video Clips & SMS Crash Alerts?
QGEN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +45.23%▲ ASCENDING CHANNEL
2026-10-30O $50.35H $50.39L $50.07C $50.22VOL 4.17M
RES: $51.85SUP: $42.52SMA50: $45.11SMA200: $42.59
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
QGEN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
18.1%/yr Implied 5Y Growth
vs. +5.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on QGEN today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for QGEN. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for QGEN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
QGEN Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is QGEN stock moving today?
Why QGEN Stock Traded Steady Today — RQD Quant Desk Flash. Accounting Warning: Paper earnings outpaced operating cash flow (+222.9% (NI vs OCF)) as receivables rose.